The researchers applied this ultrasensitive biosensor to glycoprofile HER2 in human serum samples using lectins, successfully distinguishing between a high-risk individual without breast cancer and a patient with stage 2 breast cancer. Here, ERBB2 is linked to breast carcinoma.